Zoetis Inc. (ZTS) Stock
NYSEZTS has an Alpha Score of 42 out of 100 (weak), computed on Nov 2, 2026 from 3 of 4 sub-scores. 25 members of Congress disclosed 65 trades in ZTS since 2015: 31 purchases and 34 sales, most recently Gilbert Cisneros (purchase, Sep 18, 2026). 9 of the hedge funds AlphaScala tracks reported ZTS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $229.11M. Its trailing P/E ratio is 12.6 and its net margin 27.5% (key statistics as of Oct 22, 2026).
What is ZTS's Alpha Score?
How it works →Alpha Score of 42 reflects weak overall profile with weak momentum, moderate value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 2, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Zoetis Inc. (ZTS)?
Most recent: Gilbert Cisneros (purchase, Sep 18, 2026); records start Jan 14, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-18 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-07-17 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-06-16 | purchase | $1k – $15k |
| Byron Donalds R-FL · House | 2026-06-09 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-04-14 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-13 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-02-10 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-12-19 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded ZTS, with filing lags →Which hedge funds own ZTS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 3.19M | $229.11M | +536% |
| Millennium Management Israel Englander | 1.81M | $130.34M | +10% |
| Renaissance Technologies Jim Simons (founder) | 1.40M | $100.84M | +457% |
| D.E. Shaw David Shaw | 538K | $38.63M | +615% |
| Marshall Wace | 257K | $18.50M | +4826% |
| Bridgewater Associates Ray Dalio | 134K | $9.64M | +165% |
| Soros Fund Management George Soros (founder) | 28K | $2.00M | NEW |
| Hussman Investment Trust John Hussman | 11K | $754.5K | NEW |
| Blackstone | 3K | $240.7K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are ZTS's key statistics?
Key statistics as of Oct 22, 2026
How does ZTS's valuation compare with the Healthcare sector?
| Metric | ZTS | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 12.6 | 27.1 | 97 |
| Net margin | 27.49% | 5.48% | 139 |
| Return on equity | 69.25% | 6.84% | 158 |
| Dividend yield (payers) | 1.64% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
AlphaScala analysis on ZTS
Latest 1ZTS price chart
Powered by TradingViewWhat does Zoetis Inc. do?
Zoetis Inc. is a leading animal health company that engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. It operates across seven major product categories, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals, and animal health diagnostics. The company serves a diversified portfolio of species, encompassing livestock such as cattle, swine, poultry, fish, and sheep, as well as companion animals like dogs, cats, and horses. Zoetis Inc. holds the largest market share in the animal health industry, providing essential solutions for both production animals and pets worldwide. Its offerings support veterinarians, livestock producers, and pet owners by addressing key health needs in these sectors. Founded in 2013 and headquartered in Parsippany, New Jersey, Zoetis Inc. plays a pivotal role in advancing animal care through innovative products and services.